Suppr超能文献

肝硬化来源的肝细胞癌中SOCS-1基因的甲基化介导沉默

Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis.

作者信息

Okochi Osamu, Hibi Kenji, Sakai Mitsuru, Inoue Soichiro, Takeda Shin, Kaneko Tetsuya, Nakao Akimasa

机构信息

Second Department of Surgery, Nagoya University School of Medicine, Nagoya, Japan.

出版信息

Clin Cancer Res. 2003 Nov 1;9(14):5295-8.

Abstract

PURPOSE

Suppressor of cytokine signaling-1 (SOCS-1) is a negative regulator of Janus kinase and signal transducer and activation of transcription pathway. Recently, it was demonstrated that SOCS-1 gene was silenced frequently by methylation of CpG island in human hepatocellular carcinoma (HCC). We examined the methylation-mediated silencing of SOCS-1 in tumors of HCC patients.

EXPERIMENTAL DESIGN

Fifty patients with HCC were investigated in this study. We examined the methylation status of the SOCS-1 promoter region by methylation-specific PCR and then confirmed the methylation-mediated silencing of SOCS-1 by Northern blot analysis. Furthermore, this methylation status was compared with clinicopathological findings.

RESULTS

Aberrant methylation of the SOCS-1 gene was detected in 30 of 50 (60%) HCC specimens. No corresponding nontumorous liver tissues showed SOCS-1 methylation. Subsequent Northern analysis proved that methylation of the SOCS-1 promoter inactivated translation and diminished expression of SOCS-1 mRNA. We then analyzed the correlation between the clinicopathological data and SOCS-1 aberrant methylation and found that HCC derived from liver cirrhosis had a significant relationship with SOCS-1 methylation (P = 0.0207).

CONCLUSIONS

SOCS-1 may be a novel tumor suppressor, and its aberrant methylation may be a key event for HCC transformation of cirrhotic nodules.

摘要

目的

细胞因子信号转导抑制因子1(SOCS-1)是Janus激酶和信号转导及转录激活通路的负调节因子。最近有研究表明,在人类肝细胞癌(HCC)中,SOCS-1基因常因CpG岛甲基化而沉默。我们检测了HCC患者肿瘤中SOCS-1的甲基化介导沉默情况。

实验设计

本研究调查了50例HCC患者。我们通过甲基化特异性PCR检测了SOCS-1启动子区域的甲基化状态,然后通过Northern印迹分析证实了SOCS-1的甲基化介导沉默。此外,将这种甲基化状态与临床病理结果进行了比较。

结果

在50例HCC标本中的30例(60%)检测到SOCS-1基因的异常甲基化。相应的非肿瘤肝组织未显示SOCS-1甲基化。随后的Northern分析证明,SOCS-1启动子的甲基化使翻译失活并减少了SOCS-1 mRNA的表达。然后我们分析了临床病理数据与SOCS-1异常甲基化之间的相关性,发现源自肝硬化的HCC与SOCS-1甲基化有显著关系(P = 0.0207)。

结论

SOCS-1可能是一种新型肿瘤抑制因子,其异常甲基化可能是肝硬化结节向HCC转化的关键事件。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验